Morgan Stanley adjusted its 2011 and 2013 EPS estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX) and maintained its equal-weight rating and $2 price target. The bank sees a 2011 loss of $0.32 per share, narrower than its previous
From FNNO.com, this is the Financial News Network. I’m Cleo
Stiller-Farrell and this is your Midweek Market Wrap Up. The British
Bankers’ Association, which has the supervisory role of setting the
influential Libor rates, announced that it would be willing to give up
its...
